We therefore injected either recombinant IL-9 or PBS in ABX-treated mice throughout tumour development, and found enhanced tumour control in IL-9-treated animals, as shown by a lower number of lung foci compared with animals treated with PBS (Fig. 5a). This evidence concerns the gene IL9 and neoplasm.